Ipsen at a glance

Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. We also have a well-established and successful Consumer Healthcare business. We are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.


Ipsen is a global biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neurosciences and Rare Diseases.
Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business.
With total sales close to €1.6 billion in 2016, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries.
Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has more than 5,100 employees worldwide.


Ipsen’s ambition is to be a leading global biotech company focused on innovation and Specialty Care.
Ipsen has implemented a strategy based on a sharpened focus in key therapeutic areas in Specialty Care, and the implementation of a sustainable Consumer Healthcare business through the OTx1 commercial model.

In Specialty Care, Ipsen is focused on three key therapeutic areas, Oncology, Neurosciences and Rare diseases, where Ipsen can establish a leadership position and leverage its expertise from drug development to commercialization. To complement the continued execution on its key products, including the important launches of Cabometyx® and Onivyde®, Ipsen has defined a targeted and dynamic innovation model to accelerate Specialty Care growth.
To build a sustainable pipeline of innovative assets, Ipsen will transform its R&D model by accelerating focused internal projects and externally sourcing assets.
Ipsen will continue to invest in business development through innovative deal structures with a focus on early to mid-stage assets in the three key therapeutic areas, targeting best-in-class, wholly-owned assets with global rights.
In Consumer Healthcare, to establish a sustainable and growing business, Ipsen will complete the OTx model transformation and leverage the three main market-leading brands through consumer innovations, capture the underlying market growth in emerging markets and strengthen the European business.


Ipsen’s commitment in research & development is our bold promise to launch at least one new drug or meaningful new indication every year. We will secure our future by building a pipeline of innovative medicines, establishing our leadership position in key therapeutic areas, sustainable lifecycle management and, most importantly, with great people throughout our R&D organization.
Guided by the principle of service to patients, Ipsen focuses on three therapeutic areas, oncology, neurosciences and rare diseases, developing innovative and differentiated therapies in areas of high unmet medical need. Our specialized portfolio of products, combined with our strong clinical and regulatory skillset, will allow us to continue to expand indications across existing therapies and bring new treatments for patients.
With an open innovation model in mind, we have placed our three R&D centres at the heart of internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom and Cambridge in the United States, in contact with leading academic research, medical and technology centres.

Last update 07/11/2018